L-Arginine Improves Cognitive Impairment in Hypertensive Frail Older Adults
Mone P, Pansini A, Jankauskas SS, Varzideh F, Kansakar U, Lombardi A, Trimarco V, Frullone S, Santulli G
Frontiers in cardiovascular medicine · 12. aprill 2022
AUTORITE KOKKUVÕTE
Cognitive impairment is a prevailing event in hypertensive patients and in frail older adults. Endothelial dysfunction has been shown to underlie both hypertension and cognitive dysfunction. Our hypothesis is that L-Arginine, which is known to ameliorate endothelial dysfunction, could counteract cognitive impairment in a high-risk population of hypertensive frail older adults. We designed a clinical trial to verify the effects of 4-weeks oral supplementation of L-Arginine on global cognitive function of hypertensive frail older patients. The study was successfully completed by 35 frail hypertensive elderly patients assigned to L-Arginine and 37 assigned to placebo. At follow-up, we found a significant difference in the Montreal Cognitive Assessment (MoCA) test score between the L-Arginine treated group and placebo (p: 0.0178). Moreover, we demonstrated that L-Arginine significantly attenuates Angiotensin II-induced mitochondrial oxidative stress in human endothelial cells. In conclusion, our findings indicate for the first time that oral L-Arginine supplementation significantly improves cognitive impairment in frail hypertensive older adults.
Clinical trial registration : www.ClinicalTrials.gov, identifier: NCT04962841.
Algne kokkuvõte, esitatud muutmata kujul. © Autorid, levitatakse Creative Commonsi litsentsi CC BY alusel. Täpsed tingimused on märgitud allikas: algne artikkel.
Teaduslik teave; see ei asenda tervishoiutöötaja nõuannet. Uuringu olemasolu selles raamatukogus ei ole väide meie toodete kohta.
← Kõik uuringud